Rila Therapeutics Begins Dosing First Group in Phase 1 Trial of RLA-23174, an Innovative HIPK2 Allosteric Inhibitor, to Treat Chronic Kidney Disease and Fibrosis.

Innovent announces that the NMPA of China has accepted the NDA for IBI311, an IGF-1R antibody, for the treatment of Thyroid Eye Disease.

Replicate Bioscience has reported promising initial clinical outcomes for its self-replicating RNA (srRNA) vaccine, RBI-4000, which is designed to combat rabies.

The trial, which is evaluating a continuous subcutaneous delivery of low-dose lenalidomide combined with dexamethasone and bortezomib, is progressing faster than expected.

Biotechnology firm ProJenX has obtained approval from the European Union to conduct a Phase 1 clinical trial, known as PRO-101, for prosetin, a groundbreaking MAP4K inhibitor.

Roivant Sciences has halted the development of its experimental drug RVT-2001 after an interim review of a Phase I/II clinical trial for myelodysplastic syndromes (MDS) revealed insufficient data to continue.

NervGen Pharma Corp. is nearing the completion of participant recruitment for its Phase 1b/2a clinical trial of NVG-291, a potential spinal cord injury treatment.

Osivax, a biopharmaceutical firm, has initiated a Phase 1 clinical trial for its sarbecovirus vaccine candidate, OVX033, in France.

This study explores the effectiveness of RP-1664, a selective oral inhibitor of polo-like kinase 4 (PLK4), targeting adult and adolescent patients with TRIM37-high solid tumors.

Theratechnologies Inc. has achieved a significant milestone in its Phase 1 clinical trial for sudocetaxel zendusortide.

Neurophth Therapeutics has successfully enrolled the final participant in its Phase I/II clinical study of Opvika® (Esonadogene Imvoparvovec), a treatment for Leber hereditary optic neuropathy (LHON) caused by the ND4 gene mutation.

Tharimmune, Inc. has successfully completed a Phase 1 clinical trial for TH104, a transmucosal buccal film containing nalmefene, which is well-tolerated with mild side effects.